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Pathobiochemical Mechanisms in Inflammation 
M. Jochum and H. Fritz 
Introduction 
The primary response of the organism to an inflammatory stimulus (tissue de-
struction after multiple trauma, invasive microbae, endotoxins of exogenous and 
endogenous origin, immune complexes etc.) is directed physiologically towards 
inactivating and eliminating the agent and to initiating the process of healing and 
repair. The activation of the complex interacting humoral and cellular defence 
mechanisms necessary for this purpose carries with it, however, the risk of damag-
ing healthy tissue and thus perpetuating the inflammatory process. The relation 
of stimuli, mediators, effectors, and inhibitors to each other finally determines the 
effectiveness or failure of the inflammatory response [1]. 
Out of the multitude of factors investigated hitherto, proteolytic enzymes, 
both of the plasma cascade systems (clotting, fibrinolysis, complement, kalli-
krein/kinin system) and also of lysosomal origin [from polymorphonuclear 
(PMN) granulocytes, monocytes, macrophages, mast cells], have proved to be po-
tent mediators of inflammation [2]. 
Mediators of the Humoral and Cellular Systems 
The contact between proenzymes of the cascade systems and damaged vascular 
endothelium together with the activators liberated from those cells results in the 
formation of system-specific proteases, whose activity is largely responsible for 
hemostasis and closure of the wound. Some of these proteolytic enzymes (plasma 
kallikrein, thrombin, plasmin, complement esterases), however, also produce ad-
ditional mediators of inflammation such as the vasoactive kinins, the hemostatic 
and edema-forming fibrin monomers and fibrin peptides, or the anaphylactic 
complement factors (C3a, C4a and C5a) (Fig. 1). System-specific proteases them-
selves, together with a series of polypeptides formed as a result of their proteolytic 
activity, act as potent chemotaxins and bring about the sequestration and activa-
tion of inflammatory cells (particularly P M N granulocytes) in the area of the 
wound [2,3]. 
The primary task of these cells is to remove the inflammatory stimulus by 
phagocytosis and thus to limit the inflammatory process to a significant extent 
[2-4]. Even during the binding and ingestion of "foreign" material in the infective 
focus, however, the phagocytic cells also liberate numerous aggressive substances 
(oxygen radicals, hydrolytic and proteolytic enzymes, etc.) into the surrounding 
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Fig. I. The interaction between humoral system (clotting, fibrinolysis, complement, kalli-
krein/kinin system) and the polymorphonuclear (PMN) granulocytes; FNDP = Fibronec-
tin degradation product; FDP = Fibrin/ogen degradation product; FXIIf = Factor Xllf; 
FXIIa = Factor Xlla; H F = Hageman factor; HMWK = high molecular weight kini-
nogen; PK = Prokallikrein 
environment. Once there, these substances are able to cause lasting damage to 
structural elements (basement membranes, elastin, collagen, fibronectin etc.) and 
to humoral factors (particularly proteins of the cascade systems). In this way they 
augment the inflammatory process to a significant degree [5,6]. 
When there is restricted activity of an inflammatory stimulus, activation of the 
proteolytic mediators of inflammation remains confined mainly to the local event 
by potent protease inhibitors [7]. If the primary defense mechanisms of the organ-
ism are not, however, in a position to counteract a massive stimulus (e.g., invasive 
micro-organisms in severe infection) in time, the increased formation of system-
specific proteases and the liberation of proteolytic enzymes and oxidizing sub-
stances from inflammatory cells eventually leads to the exhaustion of the func-
tional capacity of the inhibitory regulators. As a consequence, the destructive 
processes caused by proteases and the systemic manifestations of a local inflam-
matory process can no longer be prevented adequately or at all [5]. 
With regard to the pathological mechanisms involved in severe inflammation, 
the neutral proteases, elastase and cathepsin G, from the azurophilic granules of 
the P M N granulocytes, stand out as being significant among the lysosomal en-
zymes currently recognized. They are not only numerically predominant, but also 
have practically no substrate specificity [8]. After extracellular liberation, these 
proteases inactivate a series of plasma proteins, such as the protease inhibitors 
antithrombin III, a2-plasmin inhibitor, and CI inactivator [9, 10] only by a very 
few proteolytic cleavages if they are not inhibited immediately by their natural an-
tagonists, a i-protease inhibitor, a1-antichymotrypsin and a2-macroglobulin, 
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Myeloperoxidase, another enzyme localized in the azurophilic granules, catalyzes 
the reaction of hydrogen peroxide ( H 2 0 2 ) with chloride ions (Cl~) in the phago-
lysosomes. Thus it produces highly bactericidal oxidizing substances which also 
have extracellular activity and destroy humoral and structurally-bound proteins 
[11]. 
The antibacterial activity of lactoferrin, a protein formed mainly in the spe-
cific granules of granulocytes, but which is also produced by cells such as those 
of the glandular epithelium, is also well documented. It depends, in part, upon 
the catalytic function of the protein in the formation of highly reactive hydroxyl 
radicals [12]. Patients with lactoferrin deficiency suffer recurrent infections. Lac-
toferrin has been described as having a large number of other activities in addi-
tion, but many of these effects have not been confirmed by other investigators. 
The functional role of lactoferrin in inflammation can, therefore, be regarded as 
still being largely unclarified [12]. 
Studies in Patients and Experimental Animals 
Methodology 
Fundamental information relating to the extent to which proteases participate in 
an inflammatory process is obtained from the following studies: 
1. Quantitative demonstration of the liberation of lysosomal proteins and activa-
tion of system-specific proteolytic enzymes. 
2. Simultaneous demonstration of the consumption of protease inhibitors and 
plasma factors susceptible to proteolytic degradation. 
3. Use of specific exogenous protease inhibitors and antioxidants in therapeutic 
studies in experimental animals. 
Measurement of the lysosomal P M N granulocyte proteins elastase [13], mye-
loperoxidase [14], and lactoferrin [15] was carried out by means of highly specific 
sandwich enzyme immuno assays (ELISA). The normal concentrations of these 
proteins in the cells and plasma are shown in Fig. 2. With regard to elastase, it 
should be noted that the protease released extracellularly into the circulation can 
no longer be demonstrated as the active enzyme, but only as an inactive complex 
with a r p r o t e a s e inhibitor (ocl PI). The levels mentioned in the following dis-
cussion relate, however, only to the elastase moiety and not to the whole com-
plex. 
Protease inhibitors and plasma factors susceptible to proteolytic degradation 
were quantified in accordance with the methods outlined in [5]. 
The methods used in the therapeutic studies are extensively described in [16] 
and [17]. 
Clinical Studies 
Abdominal Surgery and Sepsis 
In order to measure exactly the rapid liberation and elimination of elastase during 
the acute stages of inflammation, blood samples were taken at frequent intervals 
(6—12 hourly) from patients undergoing abdominal surgery in a prospective clini-
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cal study (Director: Professor Duswald, City Surgical Clinic, University of Mu-
nich) and the amount of complexed elastase in the plasma was measured [18]. Pa-
tients with no postoperative infection (group A) had only a moderate increase (up 
to three times) after operation in comparison with the preoperative levels (60-
120 ng/ml), while in patients with sepsis, markedly increased concentrations were 
repeatedly determined in the course of the sepsis. At the time of diagnosis of sep-
sis, concentrations of complexed elastase were measured and these showed a 
mean six fold increase in group B (postoperative sepsis which was eventually 
overcome) or tenfold increase in group C (postoperative sepsis with a fatal out-
come). Individual peak levels up to 2500 ng/ml occurred in both groups. In pa-
tients with persisting sepsis (group C) the E-OL{ PI level remained significantly el-
evated, as a mean, until death, while the recovery phase in group B was accom-
panied by an obvious return to normal levels. At the same time as complexed elas-
tase increased in the plasma, a significant reduction in the inhibitory activity of 
antithrombin III and a2-macroglobulin together with the fibrin-stabilizing activ-
ity of factor XIII was detected in the patients with sepsis. The reduced activity 
of the factors named above at the onset of sepsis was restored to normal again 
in patients who overcame infection (group B), while a further decrease occured 
in those who perished (group C). 
Multiple Trauma 
In patients with multiple trauma, the concentration of the complexed elastase in 
plasma correlated with the degree of severity of the injury [19]. The group of pa-
tients under investigation (Director of the study: Dr. Dittmer, Surgical Clinic Mu-
nich-Großhadern, University of Munich) with widely differing injuries showed 
very high increases in the mean levels of elastase (up to ten times normal) up to 
about 12 h after the accident, followed by a well-defined return to normal. Inde-
pendent of each other, the whole group could be divided into three individual 
identical groups on the basis of clinical criteria, aided by a scale of severity as well 
as in accordance with the peak amount of elastase liberated. With these patients, 
Fig. 2. Localization, method 
of determination, and normal 
concentrations of the lyso-
somal proteins elastase (com-
plexed with a j-protease in-
hibitor; E-a{ PI), myelo-
peroxidase (MPO), and lac-
toferrin (LF) 
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it was not possible to establish a correlation between the concentration of the elas-
tase and the consumption of circulating plasma factors because of the large vol-
umes of blood transfused, particularly in the early days following multiple in-
jury. 
Sequential studies of the bronchoalveolar lavage fluid of eight patients with 
multiple t rauma (the samples were collected for us by Dr. Joka, Surgical Clinic, 
University of Essen) revealed a possible pathogenetic relationship between a per-
meability injury in the lung and the release of lysosomal proteins together with 
the oxygen products formed during the "respiratory burst" [20]. Even before the 
increase in extracellular fluid in the lung (as a measure of pulmonary edema), ex-
tremely high concentrations of complexed elastase, together with myeloperoxi-
dase and lactoferrin, could be measured in the lavage fluid in some patients. Since 
the latter two proteins mentioned are involved in secondary oxidative processes 
which, among other things, inactivate ax-protease inhibitor [7], the demonstra-
tion of enzymatically active elastase, in addition to E-oq Pi-complex, in a number 
of these samples is entirely comprehensible (Fig. 3). 
General Surgical Patients and Bacterial Infections 
In an extensive clinical study (Director of the study: Dr. Inthorn, Surgical Clinic 
Munich-Großhadern, University of Munich), the effect of operative trauma and 
bacterial infection of varying degrees of severity upon the release of granulocyte 
contents and upon humoral mediators of the inflammatory process was investi-
gated [21]. Elastase and lactoferrin were measured in almost identical amounts in 
plasma in individual cases. The time course of the release of both proteins showed 
a pattern of behavior that was often to a large degree identical; myeloperoxidase 
was generally detected in substantially smaller amounts than the other two lyso-
somal factors. On general review, of the measurements, however, the amount of 
elastase showed a continual rise corresponding to the extent of the inflammation, 
while mild and moderate inflammation could not be differentiated on the basis 
of lactoferrin and myeloperoxidase; the extracellular levels of these two proteins 
only reflected the degree of severity of the infection when sepsis was present 
(Fig. 4). The activation of humoral cascade systems in accordance with the sever-
ity of the inflammation was clearly documented by the increases in the anaphy-
latoxin C3a in plasma and by the consumption of plasma prokallikrein, pro-
thrombin, antithrombin III, and fibronectin. 
Therapeutic Studies in Experimental Animals 
The results shown in the clinical studies described above may be seen as a clear 
demonstration of the release of lysosomal enzymes from granulocytes and the 
ensuing extracellular proteolysis or oxidation of vital structural and humoral pro-
teins in the course of a severe inflammatory process. As a means of avoiding a 
deleterious endogenous imbalance of proteases and protease inhibitors, it ap-
peared to us that the early administration of effective exogenous inhibitors and 
antioxidants in animal experiments was promising. 
In a preliminary study of sepsis in young pigs (Director of the study: Dr. 
Welter, City Surgical Clinic, University of Munich), we were able to show that 
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Fig. 3. Granulocyte elastase (crosses) in complex with -protease inhibitor and in proteo-
lytically active form (arrows) together with myeloperoxidase (triangles) and lactoferrin 
(circles) in sequential bronchoalveolar lavage samples from two patients with multiple 
trauma. The change in extravascular lung water is added (squares) as a measure of pulmo-
nary edema 
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Fig. 4. Increasing concentrations of granulocytic proteins in the plasma of patients follow-
ing operative trauma with varying degrees of severity of postoperative inflammation. The 
number of patients (n) and the actual number of samples (in brackets) tested in each sever-
ity group are shown. Gr.I, uncomplicated course; Gr.II, a wound infection, locally con-
fined peritonitis, basal pneumonia; Gr. III, extensive soft tissue inflammation, peritonitis 
> 1 quadrant, severe bronchial pneumonia; Gr. IV, clinically diagnosed sepsis 
the relatively specific recombinant elastase cathepsin G inhibitor Eglin (isolated 
initially from the leech) significantly reduced consumption of protease inhibitors 
(antithrombin III, a2-macroglobulin) and other plasma proteins (e.g., factor 
XIII) and also the formation of interstitial pulmonary edema [16]. Meanwhile, we 
found in a more sophisticated model of sepsis (Director of the study: Dr. Siebeck, 
City Surgical Clinic, University of Munich), that Eglin in suitable doses clearly 
prevented edema in general in the organism and thus is active in counteracting 
sepsis-related hypotension and multiple organ failure [22]. 
We achieved similar, though less obviously therapeutic effects by the admin-
istration of CI inactivator, of an inhibitor of system-specific proteases (comple-
ment esterases, plasma kallikrein, plasmin), and of the antioxidant superoxide 
dismutase [17]. A further improvement in inflammatory symptoms may therefore 
be achievable in future by the combined administration of protease inhibitors and 
antioxidants. 
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